<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74202">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02139683</url>
  </required_header>
  <id_info>
    <org_study_id>HIFU-F</org_study_id>
    <nct_id>NCT02139683</nct_id>
  </id_info>
  <brief_title>Feasibility Study Assessing the Treatment of Fibroadenomata With a Circumferential Sonication Treatment With HIFU</brief_title>
  <official_title>High Intensity Focused Ultrasound for the Treatment of Fibroadenomata (HIFU-F)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theraclion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Theraclion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the treatment of fibroadenomata with a
      circumferential sonification treatment with HIFU..
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: fibroadenomata size reduction post-treatment on ultrasound imaging.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in size of fibroadenomata as recorded on ultrasound imaging</measure>
    <time_frame>Month 1, Month 3, Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Month 1, Month 3, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient recorded outcomes measures</measure>
    <time_frame>Month 1, Month 3, Month 12</time_frame>
    <description>Patient questionnaires and VAS scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean treatment time</measure>
    <time_frame>Treatment visit date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Fibroadenoma</condition>
  <arm_group>
    <arm_group_label>HIFU treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIFU treatment in patient diagnosed with fibroadenoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HIFU treatment</intervention_name>
    <description>HIFU treatment in patients with fibroadenoma</description>
    <arm_group_label>HIFU treatment</arm_group_label>
    <other_name>Echopulse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years of age

          -  Fibroadenomata diagnosed according to local hospital protocol; ultrasound alone on
             patients &lt;25 and ultrasound plus core-biopsy in patients &gt;25 (Graded B2 or less)

          -  Visible on ultrasound (Graded U2/U3)

          -  Definitive diagnosis of fibroadenomata confirmed by the Breast multi-disciplinary
             team meeting (MDT).

        Exclusion Criteria:

          -  Lesion with atypia or suspicion of phyllodes (Graded B3 or greater)

          -  Pregnant or lactating women

          -  History of laser or radiation therapy to the targeted breast
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Douek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kings College London, Guy's &amp; St Thomas' Hospitals, Department of Research Oncology</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 20, 2016</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibroadenoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
